Roivant Sciences Ltd. (ROIV)
| Market Cap | 25.07B +206.2% |
| Revenue (ttm) | 7.53M -67.6% |
| Net Income | -266.25M |
| EPS | -0.49 |
| Shares Out | 722.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,764,828 |
| Open | 37.01 |
| Previous Close | 37.58 |
| Day's Range | 34.69 - 37.13 |
| 52-Week Range | 11.85 - 37.97 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 41.82 (+20.48%) |
| Earnings Date | Aug 6, 2026 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rh... [Read more]
Financial Performance
In fiscal year 2026, Roivant Sciences's revenue was $8.26 million, a decrease of -71.57% compared to the previous year's $29.05 million. Losses were -$299.77 million, 74.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $41.82, which is an increase of 20.48% from the latest price.
News
Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month
Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a 30-day supply of their newly approved rare disease drug, Lisraya.
Roivant Sciences Transcript: FDA announcement
LISRAYA received FDA approval as the first oral-targeted therapy for dermatomyositis, launching immediately with broad label flexibility and robust efficacy and safety data from the VALOR trial. The company anticipates slow, steady adoption, strong patient support, and future expansion into additional indications.
Roivant Sciences Press release: FDA announcement
Roivant Sciences issued a press release on August 28, 2026, disclosing material business information to investors.
Roivant Sciences Slides: FDA announcement
Roivant Sciences has posted slides in relation to its latest quarterly earnings report, which was published on August 28, 2026.
US FDA approves Roivant-Priovant's skin and muscle disease drug
The U.S. Food and Drug Administration said on Thursday it approved a treatment from Roivant and partner Priovant Therapeutics for a rare disease, making it the first oral drug for the condition a...
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitini...
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of a...
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
DURHAM, N.C., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitini...
Roivant Sciences price target raised to $37 from $35 at BofA
BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $37 from $35 and keeps a Neutral rating on the shares. The firm adjusted targets for…
Roivant Sciences price target raised to $46 from $42 at Citi
Citi raised the firm’s price target on Roivant Sciences (ROIV) to $46 from $42 and keeps a Buy rating on the shares.
Roivant Sciences price target raised to $42 from $36 at Guggenheim
Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $42 from $36 and keeps a Buy rating on the shares.
Roivant Sciences price target raised to $41 from $34 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $34 and keeps a Buy rating on the shares. The firm says the…
TD Cowen boosts Roivant Sciences price target, says has many catalysts on deck
TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $50 from $41 and keeps a Buy rating on the shares following Q1 results. The firm noted Roivant…
Roivant Sciences Earnings Call Transcript: Q1 2027
Pipeline progress continues with imminent DM launch, strong cash position, and $950M from Moderna settlement. Multiple clinical readouts and launches expected in the next 18 months, with a focus on building a robust commercial foundation and ongoing capital returns.
Roivant Sciences Quarterly report: Q1 2027
Roivant Sciences has published its Q1 2027 quarterly earnings report on August 6, 2026.
Roivant Sciences Slides: Q1 2027
Roivant Sciences has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 6, 2026.
Roivant Sciences Earnings release: Q1 2027
Roivant Sciences released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
Roivant Sciences reports Q1 EPS (26c), consensus (36c)
Reports Q1 revenue $1.44M, consensus $2.34M. “This quarter has been a moment of relative quiet between our incredibly busy last twelve months and our even busier year ahead,” said Matt…
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (N...
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (P...
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), diffi...
Roivant Sciences price target raised to $35 from $31.50 at BofA
BofA raised the firm’s price target on Roivant Sciences (ROIV) to $35 from $31.50 and keeps a Neutral rating on the shares. The firm sees balanced risk/reward into Roivant’s Phase…
Roivant Sciences Proxy statement: Proxy filing
Roivant Sciences filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
Roivant Sciences Proxy statement: Proxy filing
Roivant Sciences filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, A...